Novel ligands designed to activate mu opioid receptors and provide analgesic effects without opioid-related side effects, providing specific insight into the cellular impact of opioid receptor-based activation as related to pain medications. These ligands could be used as a tool to negate drug tolerance and dependence as well as other adverse side effects.
This invention combines the strengths of two commonly used mouse strains (C57BL/6J and FVB/N) to obtain a preferable nuclear genome amenable to pronuclear injection for mouse transgenesis.
The proposed technology offers a new method to improve homing of umbilical cord blood (UCB) to bone marrow during hematopoietic stem cell (HSC) transplantation in a safe, highly efficacious, and cost-effective way.
The current invention concerns the novel use of an endogenous estrogen derivative that has a super-strong neuroprotective effect against oxidative neurotoxicity in vivo.
A novel anti-metastasis therapy for prostate cancer, utilizing the newly established small-activating RNA (saRNA) technique to up-regulate the expression of the tumor metastasis suppressor gene, dihydropyrimidase-like 3 (DPYSL3).
Novel acetylcholinesterase (AChE) inhibitors for the symptomatic treatment of Alzheimer's disease.